this is going down to 12-13 since there will be no news for months. also, there is a growing threat from immunotherapy which brings into question the relevance of 1202 and 1101. i am holding but i understand the rationale and think it will have a near term negative impact.
There has been some speculation - and that's what it is - that to achieve longer overall survival (OS), at least beyond what is currently achieved with ibrutinib, you'll need to add immunotherapy. Stated another way, adding 1101 or 1202 may lead to longer PFS but conceivably might not move the dial on OS. I tend to doubt this - my view is that you'll likely need a cocktail that includes agents beyond just immunotherapy agents, as various complex cocktails have achieved the best approach in the past for a variety of cancers. So, 1101 and 1202 seem in an optimal position since they are potent inhibitors for their respective pathways and, due to their safety profile, could likely be used in combination with a variety of oncology agents, including ibrutinib and immunotherapy agents (and that's basically what is going on in the ongoing clinical trials). Anyway, I'm holding. In the past, and this goes back to 2008-09, holding based on a solid scientific thesis has proven to be the best approach.
did you buy on butter or margarine? i prefer butter
I think it's down on no news for a while - that is, nothing to report any time soon so some investors are shifting out of the stock. i'm a long, and I bought at 3.70, so it's a pain but I've seen it before. should have waited
trust me - TGTX is on the radar of several companies and this attention will only increase as additional data comes out in relation to 1101 and 1202. Many larger firms are holding back a bit until they see more mature phase II or even phase III data - in some cases, they'd rather have more certainty about the likelihood of clinical success, even if this means paying more for the biotech.
when did you get let go by AERI? i'm guessing it was recently
not sure what Bill is complaining about. I have a "risk" account in which i make concentrated bets on biotechs. I'm down about 800k in this downdraft but have long time horizon and am not that depressed (at least not yet)
and there is zero chance of you making money on your FCX long position which you've owned since the stock was twice what it is now. That is, unless you hold for several years.
Could be right regarding immunotherapy but i have seen very little commentary on that point. But it's true that TGTX is selling off much more than other smaller biotechs so sentiment has definitely shifted against it. i'm still long but would like to hear the thoughts of others.